

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

THE INDUCTION OF CALVING USING BETAMETHASONE
AND THE PHARMACOLOGICAL ACTIVITY OF SELECTED
FORMULATIONS HAVING DIFFERENT RATES OF
ABSORPTION

A thesis presented in partial fulfilment
of the requirements for the
Degree of Doctor of Philosophy
at Massey University

STUART CAMPBELL MacDIARMID

1982

03-10048

Abstract of a thesis presented in partial fulfilment of the requirements for the Degree of Doctor of Philosophy.

THE INDUCTION OF CALVING USING BETAMETHASONE AND THE PHARMACOLOGICAL ACTIVITY OF SELECTED FORMULATIONS HAVING DIFFERENT RATES OF ABSORPTION

by Stuart Campbell MacDiarmid

A series of experiments was undertaken in cows to study the disposition and duration of activity of selected formulations of the synthetic corticosteroid betamethasone (BM). The aim was to select a combination of formulations which would be suitable for use in a two-injection treatment regimen designed to induce premature parturition in cattle.

In an initial experiment, 10 cows each received a subcutaneous injection of 20 ml of 2 mg/ml aqueous suspension of BM, 10 received 2 ml of a 20 mg/ml suspension and a further 10 cows served as saline-treated controls. The BM formulations differed only in their solids:vehicle ratio. Plasma BM, cortisol and glucose concentrations, and differential blood cell counts were studied for 3 days before, and for 19 days after, treatment.

The 2 mg/ml suspension produced a markedly higher peak plasma BM concentration than the 20 mg/ml suspension. However, plasma BM levels tended to be maintained for longer by the suspension having the higher solids:vehicle ratio.

The administration of BM resulted in depression of early-morning cortisol concentrations, elevation of plasma glucose levels, and elevation of circulating neutrophil numbers. The magnitude and duration of these changes was related to the solids:vehicle ratio of the injected suspensions, with the more concentrated formulation producing effects of greater duration.

A second experiment involved 9 cows which were divided into 3 groups, each of which was treated at a dose rate of

0.1 mg/Kg with sodium phosphate solution or a 2 mg/ml BM suspension or a 20 mg/ml BM suspension. Over a period of several weeks each cow received its allocated formulation by each of 3 routes; intravenous, intramuscular and subcutaneous.

The bioavailability of the BM suspensions was low and the solids:vehicle ratio exerted a profound effect on the rate at which the steroid was absorbed. The disposition curves of the BM solution were similar regardless of the route of administration and the plasma half-life values of BM sodium phosphate, estimated from 3 experiments in each of 3 cows, were 5.64, 6.06 and 6.43 hours.

Ten cows were included in a third experiment. They were treated by subcutaneous injection with 2 ml of a 10 mg/ml BM suspension; a preparation intended for use in the induction of calving. Mean plasma concentrations of BM and glucose were elevated above pre-treatment values for 4 days and 8 days respectively. Mean plasma cortisol levels were profoundly depressed for 2 weeks and in some individuals showed no signs of returning to normal 4 weeks after treatment.

Two field trials, involving 619 and 553 cows respectively, were conducted to assess the suitability of BM formulations for the induction of premature calving in commercial dairy herds.

In the first trial, the mean stage of pregnancy at which cows were treated was approximately 250 days. Cows received an initial injection of either 2 ml of a 10 mg/ml suspension of BM, 2 ml of a 15 mg/ml BM suspension or 4 ml of a 5 mg/ml suspension of dexamethasone trimethylacetate (DTMA). All cows which had not calved within 10 days of this initial treatment received a 12.5 ml dose of a 2 mg/ml suspension of BM.

In comparison with those cows treated with DTMA, significantly fewer cows treated with the concentrated BM suspensions required a second corticosteroid injection. In all other respects, such as calf mortality, incidence of retained foetal membranes and maternal illnesses, the results

of the treatments were not significantly different. The 10 mg/ml BM suspension was therefore deemed to be suitable for use in the induction of calving.

The second field trial confirmed the suitability of the 10 mg/ml suspension as an initial treatment to induce calving. Cows which had not calved within 7 days of the initial treatment were injected with 20 mg of BM, either as a 2 mg/ml suspension or as a 2 mg/ml solution of the sodium phosphate ester.

After the second steroid injection, those cows which had received the more rapidly absorbed BM solution calved sooner than those which had been treated with the 2 mg/ml suspension.

The results of these studies clearly showed that the duration of activity of BM suspensions could be prolonged by increasing their solids:vehicle ratio. It was also shown that a treatment regimen consisting of an initial injection of a 10 mg/ml BM suspension, followed 7 to 10 days later by an injection of a more rapidly absorbed BM formulation, was suitable for the induction of calving as currently practised in New Zealand.

ACKNOWLEDGEMENTS

I wish to gratefully acknowledge the advice, encouragement and assistance of my chief supervisor, Dr B.S. Cooper.

My thanks are also due to my supervisor, Dr K.R. Lapwood, whose advice on the subject of radioimmunoassays was particularly helpful.

I received invaluable advice regarding experimental design and statistical analysis from Professor R.E. Munford and the late Dr R.E. Harris.

Dr R.J. Fairclough of Ruakura Agricultural Research Centre kindly provided cortisol antiserum, and Dr K.J. Child of Glaxo Group Research Ltd., London, betamethasone antiserum.

I thank Miss Geraldine Borrie for carrying out the majority of the plasma glucose estimations, Mr J. Elgar for assisting with some of the radioimmunoassays and Mr G. Locke, Mr J. Thompson and Mr V. Smith for their help in the restraint and care of experimental animals.

I am grateful to the staff and clients of Cambridge Veterinary Services Inc. for their co-operation in the two field trials, and to Glaxovet Australia Pty. Ltd. for supplying the betamethasone sodium phosphate used in one of those trials.

Finally, I must express my sincere thanks to Glaxo New Zealand Limited for their generous financial support, and to Mr D.J. Jull, Technical Director of that company, for his advice and encouragement.

TABLE OF CONTENTS

	Page	
CHAPTER I	INTRODUCTION	1
CHAPTER II	THE ABSORPTION OF DRUGS FROM SUBCUTANEOUS AND INTRAMUSCULAR INJECTION SITES: A REVIEW	5
CHAPTER III	A COMPARISON OF THE PHARMACOLOGICAL ACTIVITY IN COWS OF TWO SUSPENSIONS OF BETAMETHASONE ALCOHOL	44
CHAPTER IV	THE DISPOSITION OF CERTAIN BETAMETHASONE FORMULATIONS ADMINISTERED TO CATTLE BY DIFFERENT PARENTERAL ROUTES	72
CHAPTER V	THE PHARMACOLOGICAL ACTIVITY IN COWS OF a 10 MG/ML SUSPENSION OF BETAMETHASONE	101
CHAPTER VI	INDUCTION OF PARTURITION IN CATTLE USING CORTICOSTEROIDS : A REVIEW	115
CHAPTER VII	A COMPARISON BETWEEN SUSPENSIONS OF BETAMETHASONE, AND DEXAMETHASONE TRIMETHYLACETATE, USED FOR THE INDUCTION OF PARTURITION IN DAIRY COWS	165
CHAPTER VIII	A COMPARISON OF DIFFERENT FORMULATIONS OF BETAMETHASONE USED FOR THE INDUCTION OF PARTURITION IN DAIRY COWS	178
CHAPTER IX	GENERAL DISCUSSION	193
REFERENCES		197
APPENDICES		222

LIST OF FIGURES

Figure		Page
3:1	Representative standard curve for the cortisol assay, computed by the method of Burger <i>et al</i> (1972).	50
3:2	Representative standard curve for the betamethasone assay, computed by the method of Burger <i>et al</i> (1972).	54
3:3	Plasma betamethasone concentrations (means and CL ₉₅ s) in cows following administration of two different formulations at a dose rate of 40 mg/cow. Group I; 2 mg/ml suspension Group II; 20 mg/ml suspension Group III; saline-treated control group.	59
3: 4	Early morning plasma cortisol concentrations (means and CL ₉₅ s) in cows before and after administration of two betamethasone formulations at a dose rate of 40 mg/cow. Group I; 2 mg/ml suspension. Group II; 20 mg/ml suspension. Group III; saline-treated control group.	63
3:5	Plasma glucose concentrations (means and CL ₉₅ s) in cows treated with two betamethasone formulations at a dose rate of 40 mg/cow. Group I; 2 mg/ml suspension. Group II; 20 mg/ml suspension. Group III; saline-treated control group.	64
3:6	Differential white blood cell counts (means $\pm$ SD) in cows treated with two betamethasone formulations at a dose rate of 40 mg/cow. Group I; 2 mg/ml suspension. Group II; 20 mg/ml suspension. Group III; saline-treated control group.	68
4:1	Semilogarithmic graph depicting plasma concentrations of betamethasone after intravenous injection of the sodium phosphate ester at a dose rate of 0.1 mg/kg to a single cow (no. 128).	76
4.2	Semilogarithmic graph depicting the plasma concentration of betamethasone after intramuscular injection of the 2 mg/ml suspension at a dose rate of 0.1 mg/kg to a single cow (no. 128).	79

Figure		Page
4:3	The absorption half-life of betamethasone sodium phosphate administered by extravascular injection to cattle. (Calculated by the method of Swintosky, Dittert & Doluisio, 1969). a. The $t_{1/2ab}$ calculated at this point applied to all the intramuscular injections as well as to one subcutaneous injection (cow no. 34). b. The $t_{1/2ab}$ calculated at this point applied to the subcutaneous injection in cows no 41 and 62.	81
4:4	Mean plasma concentrations of betamethasone in adult cattle (Group I) following parenteral administration of the sodium phosphate ester at a dose rate of 0.1 mg/kg.	82
4:5	Plasma concentrations of betamethasone following intramuscular injection of the sodium phosphate ester (4 mg/ml) at a dose rate of 0.1 mg/kg to a single cow (no. 41).	87
4:6	Plasma concentrations (means and CL_{95}) of betamethasone following intravenous injection of different formulations to cows at a dose rate of 0.1 mg/kg.	90
4:7	Plasma concentrations of betamethasone (means and CL_{95}) following intramuscular injection of different suspensions to cows at a dose rate of 0.1 mg/kg.	94
4:8	Plasma concentrations of betamethasone (means and CL_{95}) following subcutaneous injection of different suspensions to cows at a dose rate of 0.1 mg/kg.	94
5:1	Plasma concentrations of betamethasone (means and CL_{95}) in cows following subcutaneous injection of 2 ml of a 10 mg/ml suspension. Horizontal lines indicate the pretreatment mean and its upper CL_{95} .	105
5:2	Mean plasma betamethasone concentrations in 3 cows over a 48 hour period following the subcutaneous injection of 2 ml of a 10 mg/ml suspension.	105
5:3	Early-morning plasma cortisol concentrations (means and CL_{95}) in cows following the subcutaneous injection of 2 ml of a 10 mg/ml suspension of betamethasone. Horizontal lines indicate the pretreatment mean and its upper and lower CL_{95} .	

Figure		Page
5:4	Early-morning plasma cortisol concentrations in 2 cows following subcutaneous injection of 2 ml of a 10 mg/ml suspension of betamethasone.	108
5:5	Plasma glucose concentrations (means and CL_{95}) in cows following subcutaneous injection of 2 ml of a 10 mg/ml suspension of betamethasone. Horizontal lines indicate pretreatment mean and its upper CL_{95} .	111
7:1	Calving pattern after induction of parturition using corticosteroids. Group I; 2 ml of a 10 mg/ml suspension of betamethasone. Group II; 2 ml of a 15 mg/ml suspension of betamethasone. Group III; 4 ml of a 5 mg/ml suspension of dexamethasone TMA. Second injection; 12.5 ml of a 2 mg/ml suspension of betamethasone.	172
8:1	Calving pattern after induction of parturition using betamethasone formulations. Group I; those cows calving within 7 days of receiving 2 ml of a 10 mg/ml suspension. Group II; 2 ml of a 10 mg/ml suspension followed by 10 ml of 2 mg/ml suspension (second injection). Group III; 2 ml of a 10 mg/ml suspension followed by 10 ml of a 2 mg/ml solution (second injection).	184

LIST OF TABLES

Table		Page
2:I	Stages in the absorption of drugs from injected suspensions (Dowrick, 1980).	21
2:II	The effect of alterations of concentration and volume on the absorption of injected aqueous solutions.	24
2:III	Classification of parenteral formulations according to rate of absorption (after Ritschel, 1973).	42
3:I	Specificity of antiserum to cortisol-3 BSA. Cross reaction with other steroids (Evans, 1979).	52
3:II	Cortisol assay: between assay coefficients of variation.	52
3:III	Cortisol assay: within assay coefficients of variation.	52
3:IV	Specificity of antiserum to betamethasone-CMO-thyroglobulin. Cross reaction with other steroids (Bradley et al, pers. com.).	55
3:V	Betamethasone assay: between assay coefficients of variation.	55
3:VI	Betamethasone assay: within assay coefficients of variation.	55
3:VII	Summary of the analysis of variance of betamethasone concentrations in the plasma of cows treated with two different formulations.	60
3:VIII	Early-morning plasma cortisol levels in untreated cows over a twenty-two day period.	61
3:IX	Summary of the analysis of variance of cortisol in the plasma of cows treated with two betamethasone formulations.	65
3:X	Summary of the analysis of variance of plasma glucose concentrations in cows treated with two betamethasone formulations.	66
4:I	Days from commencement of experiment on which different betamethasone formulations were administered to cows.	74

Table		Page
4:II	Plasma betamethasone concentrations (ng/ml) in cows following the administration of betamethasone sodium phosphate solution, 4 mg/ml, at a dose rate of 0.1 mg/kg	83
4:III	Disposition kinetics of betamethasone in cattle following intravenous injection of the sodium phosphate solution (0.1 mg/kg). Single compartment open model.	85
4:IV	Body clearance of betamethasone in cows following the intravenous injection of betamethasone sodium phosphate, 0.1 mg/kg.	86
4:V	Elimination kinetics of betamethasone following the administration of the sodium phosphate ester by different routes. Dose, 0.1 mg/kg.	88
4:VI	Plasma concentration of betamethasone (ng/ml) following extravascular injection of suspensions of different concentrations. Dose, 0.1 mg/kg.	91
4:VII	Disposition kinetics of betamethasone in cattle following extravascular injection of a 2 mg/ml suspension. Dose, 0.1 mg/kg.	93
4:VIII	Area under disposition curve (ng/ml.hr) and relative bioavailability (%) of betamethasone alcohol following extravascular administration to cows. Dose, 0.1 mg/kg.	93
5:I	Early-morning plasma cortisol concentrations in cows over the six sampling days before treatment.	109
5:II	Plasma glucose concentrations in cows: pretreatment concentrations and peak concentrations following subcutaneous injection of 2 ml of betamethasone alcohol suspension, 10 mg/ml.	110
6:I	The incidence of RFMs in different trials using short-acting corticosteroids within 3 weeks of term.	153
7:I	Stage of pregnancy and days before expected calving (mean $\pm$ S.D.) on which the first injection was administered (restricted category).	170
7:II	Response time in days (mean $\pm$ S.D.) between first injection and calving.	171
7:III	Cows calving following first injection and cows calving within 7 days of second injection.	171
7:IV	Prematurity of calves (mean $\pm$ S.D.) born to cows in the restricted category.	173

Table		Page
7:V	Number (%) of calves stillborn and dying within 4 days of birth following induction of parturition.	174
7:VI	Incidence of metabolic disease amongst cows induced to calve by the administration of corticosteroids.	174
7:VII	Incidence of retained foetal membranes amongst cows induced to calve by the administration of corticosteroids.	175
8:I	Stage of pregnancy and number of days before expected calving (mean $\pm$ S.D.) on which first injection administered (restricted category).	182
8:II	Response time (mean $\pm$ S.D.) between first injection and calving.	182
8:III	Number (%) of cows calving within a specified time after receiving a second injection of betamethasone.	183
8:IV	Prematurity of calves born to cows in the restricted category.	185
8:V	Number (%) of calves stillborn and dying within 4 days of birth following induction of parturition.	185
8:VI	Birth weights (mean $\pm$ S.D.) of calves born following induction of parturition.	186
8:VII	Incidence of periparturient illness in cows induced to calve using betamethasone formulations.	187
8:VIII	Comparison of the stage of gestation in days (mean $\pm$ S.D.) at which the first injection was administered in the 1978 trial and the 1979 trial.	188
8:IV	Comparison of prematurity at birth in days (mean $\pm$ S.D.) of calves born in the 1978 trial and the 1979 trial.	189